Difference between revisions of "Diaz-Padilla I, et al. Gynecol. Oncol. (2015) cited as Ref 587 in DOI: 10.1038/s41392-020-0110-5 (Q9850)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: Publication Date (P100): 2015, #quickstatements; #temporary_batch_1590002823654)
(‎Created claim: Page(s) (P105): 216-222, #quickstatements; #temporary_batch_1590074839150)
 
(3 intermediate revisions by the same user not shown)
Property / Published In Name String
 +
Gynecol. Oncol.
Property / Published In Name String: Gynecol. Oncol. / rank
 +
Normal rank
Property / Volume
 +
137
Property / Volume: 137 / rank
 +
Normal rank
Property / title
 +
A phase II study of single-agent RO4929097 a gamma-secretase inhibitor of Notch signaling in patients with recurrent platinum-resistant epithelial ovarian cancer: a study of the Princess Margaret Chicago and California phase II consortia (English)
Property / title: A phase II study of single-agent RO4929097 a gamma-secretase inhibitor of Notch signaling in patients with recurrent platinum-resistant epithelial ovarian cancer: a study of the Princess Margaret Chicago and California phase II consortia (English) / rank
 +
Normal rank
Property / Page(s)
 +
216-222
Property / Page(s): 216-222 / rank
 +
Normal rank

Latest revision as of 15:46, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Diaz-Padilla I, et al. Gynecol. Oncol. (2015) cited as Ref 587 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Diaz-Padilla I
    0 references
    0 references
    2015
    0 references
    Gynecol. Oncol.
    0 references
    137
    0 references
    A phase II study of single-agent RO4929097 a gamma-secretase inhibitor of Notch signaling in patients with recurrent platinum-resistant epithelial ovarian cancer: a study of the Princess Margaret Chicago and California phase II consortia (English)
    0 references
    216-222
    0 references